Skip to content

Randomized Controlled Trial Comparing Letrozole-Induced Ovulation Versus Natural Cycle Single-Blastocyst Frozen Embryo Transfer on Pregnancy Outcomes in Normally Ovulatory Women

Randomized Controlled Trial Comparing Letrozole-Induced Ovulation Versus Natural Cycle Single-Blastocyst Frozen Embryo Transfer on Pregnancy Outcomes in Normally Ovulatory Women

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500114189
Enrollment
Unknown
Registered
2025-12-09
Start date
2025-07-22
Completion date
Unknown
Last updated
2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

?Outcome of Frozen Embryo Transfer

Interventions

Letrozole group:Starting on day 3 of the menstrual cycle, administer letrozole 2.5 mg orally once daily for 4 days. Five days later, perform dynamic ultrasound monitoring of follicular development, an
Natural Cycle Group:Based on the length of the menstrual cycle, transvaginal ultrasound monitoring is initiated on day D8–D11, followed by ultrasound examinations every 1–3 days according to the rate

Sponsors

Beijing Chao-Yang Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Regular menstrual cycles (defined as 21–35 days); 2. Aged 20–40 years; 3. Scheduled to undergo frozen-thawed single blastocyst transfer (including IVF/ICSI cycles); 4. Normal-range BMI (18.5–24 kg/m^2); 5. Availability of >=1 cryopreserved blastocyst(s) with Gardner morphology score >=4BC from IVF/ICSI cycles;

Exclusion criteria

Exclusion criteria: 1. History of >=2 previous embryo transfers without achieving clinical pregnancy; 2. Embryos scheduled for thawing derived from oocyte cryopreservation or subjected to repeated freeze-thaw cycles; 3. Untreated uterine pathologies affecting endometrial receptivity (e.g., uterine malformations, submucosal myomas >=1.5 cm, adenomyosis with junctional zone >=7 mm, or intrauterine adhesions); 4. Untreated ultrasonographically visible hydrosalpinx (defined as fluid-filled dilated fallopian tubes >=10 mm); 5. Previous cycle cancellation due to inadequate endometrial thickness (<7 mm) during frozen embryo transfer preparation; 6. Documented immune disorders (e.g., antiphospholipid syndrome, systemic lupus erythematosus with positive anti-dsDNA, active rheumatic diseases); 7. Parental chromosomal abnormalities (excluding benign polymorphisms).

Design outcomes

Primary

MeasureTime frame
Ongoing pregnancy;

Secondary

MeasureTime frame
Early miscarriage;Biochemical pregnancy;Clinical pregnancy;Ectopic pregnancy;

Countries

China

Contacts

Public ContactPan Ye

Beijing Chao-Yang Hospital, Capital Medical University

panyecrystal@163.com+86 17865126119

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026